Document Type

Article

Publication Date

1-13-2020

Publication Title

Molecular Neurodegeneration

First page number:

1

Last page number:

13

Abstract

Background: Successful development of agents that improve cognition and behavior in Alzheimer’s disease (AD) is critical to improving the lives of patients manifesting the symptoms of this progressive disorder. Discussion: There have been no recent approvals of cognitive enhancing agents for AD. There are currently 6 cognitive enhancers in Phase 2 trials and 4 in phase 3. They represent a variety of novel mechanisms. There has been progress in developing new treatments for neuropsychiatric symptoms in AD with advances in treatment of insomnia, psychosis, apathy, and agitation in AD. There are currently 4 AD-related psychotropic agents in Phase 2 trials and 7 in Phase 3 trials. Many novel mechanisms are being explored for the treatment of cognitive and behavioral targets. Progress in trial designs, outcomes measures, and population definitions are improving trial conduct for symptomatic treatment of AD. Conclusions: Advances in developing new agents for cognitive and behavioral symptoms of AD combined with enhanced trial methods promise to address the unmet needs of patients with AD for improved cognition and amelioration of neuropsychiatric symptoms.

Keywords

Neuropsychiatry; Alzheimer’s disease; Psychosis; Apathy; Agitation; Depression; Drug development; Clinical trials; Cognition

Disciplines

Cognitive Neuroscience

File Format

pdf

File Size

746 KB

Language

English

Comments

Article contains an error in the spelling of Masupirdine. All instances of ‘Masuperdine’ should thus be considered as ‘Masupirdine’. See correction to article at: https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-021-00446-3

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

UNLV article access

Search your library

COinS